No clear benefit of cellular therapy consolidation for patients achieving remission after post-HCT AML relapse
H. Moses Murdock(Dana-Farber Cancer Institute), Robert J. Soiffer(Dana-Farber Cancer Institute), Jerome Ritz(Dana-Farber Cancer Institute), Prashant Nageshwar, Eric S. Winer(Providence College), Maximilian Stahl(Harvard University), Roman M. Shapiro(Boston University), Marlise R. Luskin(Dana-Farber Cancer Institute), Rahul S. Vedula(Harvard University), Corey Cutler(Harvard University), John Koreth(Otsuka (Japan)), Vincent T. Ho(Dana-Farber Cancer Institute), Mahasweta Gooptu(Harvard University), Haesook T. Kim(Dana-Farber Cancer Institute), Catherine J. Wu(Dana-Farber Cancer Institute), Martha Wadleigh(Dana-Farber Cancer Institute), Shai Shimony(Twitter (United States)), Evan C. Chen(Dana-Farber Cancer Institute), Katie Maurer(Broad Institute), Rizwan Romee(Washington University in St. Louis), Amar H. Kelkar(Harvard University), Heather Garrity(Harvard University), Virginia O. Volpe(UConn Health), Richard M. Stone(Dana-Farber Cancer Institute), Daniel J. DeAngelo(Dana-Farber Cancer Institute), Jacqueline S. Garcia(Dana-Farber Cancer Institute), Joseph H. Antin(Harvard University), Sarah Nikiforow(Otsuka (Japan))
Cited by 3
Related Papers
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report
|Biology of Blood and Marrow Transplantation|2014|5.4k
Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity
|Cell|2015|4.2k